Erratum: Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice (Blood (2015) 126: 21 (2415-2423) DOI: 10.1182/blood-2015-05-644401);Coagulation factor v mediates inhibition of tissue factor signaling by activated protein C in mice

Blood

Volumn 126, Issue 21, 2015, Pages 2415-2423

  Liang, Hai Po H ^a,g   Kerschen, Edward J ^a   Basu, Sreemanti ^a   Hernandez, Irene ^a   Zogg, Mark ^a   Jia, Shuang ^b   Hessner, Martin J ^b   Toso, Raffaella ^c   Rezaie, Alireza R ^d   Fernández, José A ^e   Camire, Rodney M ^c   Ruf, Wolfram ^e,f   Griffin, John H ^e   Weiler, Hartmut ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; PROTEIN S; THROMBOPLASTIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; MORTALITY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STAPHYLOCOCCAL BACTEREMIA; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; SEPSIS; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TRANSGENIC MOUSE;

ANIMALS; FACTOR V; MICE; MICE, TRANSGENIC; PROTEIN C; PROTEIN S; SEPSIS; SIGNAL TRANSDUCTION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THROMBOPLASTIN;

EID: 84948989408     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-04-845131     Document Type: Erratum

References (57)

1. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32(Suppl 1):49-60.
2. Mosnier LO, Griffin JH. Protein C anticoagulant activity in relation to anti-inflammatory and antiapoptotic activities. Front Biosci. 2006;11:2381-2399.
3. Dahlbäck B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol. 2005;25(7):1311-1320.
4. Weiler H. Multiple receptor-mediated functions of activated protein C. Hamostaseologie. 2011; 31(3):185-195.
5. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007; 109(8):3161-3172.
6. Dahlbäck B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett. 2005;579(15):3310-3316.
7. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD81 dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 2010;120(9):3167-3178.
8. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007;204(10):2439-2448.
9. Cao C, Gao Y, Li Y, Antalis TM, Castellino FJ, Zhang L. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest. 2010;120(6):1971-1980.
10. Mosnier LO, Zampolli A, Kerschen EJ, et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood. 2009;113(23):5970-5978.
11. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost. 2010;8(3):445-453.
12. Cramer TJ, Gale AJ. The anticoagulant function of coagulation factor V. Thromb Haemost. 2012; 107(1):15-21.
13. Kerlin BA, Yan SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102(9):3085-3092.
14. Kerschen E, Hernandez I, Zogg M, Maas M, Weiler H. Survival advantage of heterozygous factor V Leiden carriers in murine sepsis. J Thromb Haemost. 2015;13(6):1073-1080.
15. Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000;96(13):4222-4226.
16. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
17. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413(6851):74-78.
18. Elphick GF, Sarangi PP, Hyun YM, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood. 2009;113(17):4078-4085.
19. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104(6):1740-1744.
20. Qureshi SH, Yang L, Manithody C, Bae JS, Rezaie AR. Functional properties and active-site topographies of factor X Gla-and prothrombin Gla-domain chimeras of activated protein C. Biochim Biophys Acta. 2008;1780(9):1080-1086.
21. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood. 1995;85(12):3405-3411.
22. Zhu H, Toso R, Camire RM. Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state. J Biol Chem. 2007;282(20):15033-15039.
23. Furlan-Freguia C, Marchese P, Gruber A, Ruggeri ZM, Ruf W. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest. 2011;121(7):2932-2944.
24. Tucker EI, Verbout NG, Leung PY, et al. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood. 2012;119(20):4762-4768.
25. van der Neut Kolfschoten M, Dirven RJ, Vos HL, Tans G, Rosing J, Bertina RM. Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679. J Biol Chem. 2004;279(8):6567-6575.
26. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999; 223(1):77-92.
27. Liang HP, Kerschen EJ, Hernandez I, et al. EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPStriggered interferon responses in mice. Blood. 2015;125(18):2845-2854.
28. Bhattacharjee G, Ahamed J, Pedersen B, et al. Regulation of tissue factor-mediated initiation of the coagulation cascade by cell surface grp78. Arterioscler Thromb Vasc Biol. 2005;25(8):1737-1743.
29. Schoenmakers SH, Brüggemann LW, Groot AP, Maijs S, Reitsma PH, Spek CA. Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice. J Thromb Haemost. 2005;3(12):2738-2744.
30. Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res. 2010;125(2):119-123.
31. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost. 2004;2(8):1429-1435.
32. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15(11):1318-1321.
33. Toltl LJ, Austin RC, Liaw PC. Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. J Thromb Haemost. 2011;9(3):582-592.
34. Larsen KS, Ostergaard H, Olsen OH, Bjelke JR, Ruf W, Petersen LC. Engineering of substrate selectivity for tissue factor.factor VIIa complex signaling through protease-activated receptor 2. J Biol Chem. 2010;285(26):19959-19966.
35. Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem. 2004;279(22):23038-23044.
36. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-1882.
37. Disse J, Petersen HH, Larsen KS, et al. The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem. 2011;286(7):5756-5767.
38. Disse J, Ruf W. Endothelial protein C receptor is required for tissue factor ternary complex signaling in the mouse. J Thromb Haemost. 2011; 9(12):2516-2518.
39. Rios-Steiner JL, Murakami MT, Tulinsky A, Arni RK. Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum. J Mol Biol. 2007; 371(3):774-786.
40. Bae JS, Yang L, Manithody C, Rezaie AR. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J Biol Chem. 2007;282(12):9251-9259.
41. Harmon S, Preston RJ, Ni Ainle F, et al. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem. 2008;283(45):30531-30539.
42. Yang L, Bae JS, Manithody C, Rezaie AR. Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. J Biol Chem. 2007;282(35):25493-25500.
43. Gale AJ, Sun X, Heeb MJ, Griffin JH. Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Sci. 1997;6(1):132-140.
44. Preston RJ, Ajzner E, Razzari C, et al. Multifunctional specificity of the protein C/ activated protein C Gla domain. J Biol Chem. 2006;281(39):28850-28857.
45. Deng T, Zhang Y, Chen Q, Yan K, Han D. Toll-like receptor-mediated inhibition of Gas6 and ProS expression facilitates inflammatory cytokine production in mouse macrophages. Immunology. 2012;135(1):40-50.
46. Thorelli E, Kaufman RJ, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem. 1998;273(26):16140-16145.
47. Camire RM, Bos MH. The molecular basis of factor V and VIII procofactor activation. J Thromb Haemost. 2009;7(12):1951-1961.
48. Lyden P, Levy H, Weymer S, et al. Phase 1 safety, tolerability and pharmacokinetics of 3K3AAPC in healthy adult volunteers. Curr Pharm Des. 2013;19(42):7479-7485.
49. Schuijt TJ, Bakhtiari K, Daffre S, et al. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein. Circulation. 2013;128(3):254-266.
50. Fernandes N, Mosnier LO, Tonnu L, Heeb MJ. Zn(1)-containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor. J Thromb Haemost. 2010;8(9):1976-1985.
51. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934-2943.
52. Steen M, Norstrøm EA, Tholander AL, et al. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood. 2004;103(9):3381-3387.
53. Nogami K, Shinozawa K, Ogiwara K, et al. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Blood. 2014; 123(15):2420-2428.
54. Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct plateletderived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem. 2004; 279(4):2383-2393.
55. Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood. 2004;103(11):4173-4179.
56. Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem. 1993;268(28):21130-21136.
57. Hoekema L, Nicolaes GA, Hemker HC, Tans G, Rosing J. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry. 1997;36(11):3331-3335.